Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Immunology/Autoimmune Disease

Autoimmune Disease

69

Pipeline Programs↗

87

Active Trials↗

38

Companies Involved↗

Autoimmune Disease is a moderately active landscape with 69 programs across 38 companies. The most active players are Nanjing Legend Biotech Co., China Immunotech (Beijing) Biotechnology Co., Ltd., Chongqing Precision Biotech Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

49/100

Mech. Concentration

14/100

Completion Rate

69/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Nanjing Legend Biotech Co.

2 programs

China Immunotech (Beijing) Biotechnology Co., Ltd.

1 program

Chongqing Precision Biotech Co., Ltd

1 program

Century Therapeutics, Inc.

1 program

Fate Therapeutics

1 program

Artiva Biotherapeutics, Inc.

1 program

Pipeline

Programs by Phase

Preclinical23

Hydroxychloroquine

Jazz Pharmaceuticals

Guselkumab

Johnson & Johnson

Methylprednisolone

Pfizer

Meropenem

B. Braun Medical Inc.

Ipilimumab

Bristol-Myers Squibb

Phase 134

Fludarabine

Sanofi

YTS109 Cell

China Immunotech (Beijing) Biotechnology Co., Ltd.

Cyclophosphamide

Baxter Healthcare Corporation

Rituximab

Roche

Bendamustine

Azurity Pharmaceuticals

Phase 212

Melphalan

Apotex Inc.

Cytarabine

Teva

Prednisone

Roxane Laboratories

Etoposide

Avyxa

Carmustine

Melissa K Accordino

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

56programs

Small molecule2850%

Cell therapy2138%

Monoclonal antibody47%

Protein / enzyme24%

Vaccine12%

Modality classified for 100% of 69 pipeline programs.

Analysis

Trial Status

123

clinical trials

Recruiting53 · 43%

Not yet recruiting27 · 22%

Completed20 · 16%

Unknown status7 · 6%

Terminated4 · 3%

Active, not recruiting4 · 3%

Other8 · 7%

Clinical Trials

Trial Activity

123 trials

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Recruiting·JJuventas Cell Therapy Ltd.·Phase 1·NCT06316791·24 enrolled

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06056921·24 enrolled

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Recruiting·RRenJi Hospital·Phase 1·NCT06249438·30 enrolled

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Recruiting·—·Phase 1·NCT06464679·72 enrolled

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Recruiting·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·N/A·NCT06361745·10 enrolled

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

Recruiting·NNanjing Bioheng Biotech Co., Ltd.·Phase 1·NCT06775912·18 enrolled

Clinical Study of AFN50 Injection in the Autoimmune Diseases

Recruiting·AAlphaNa Bioscience Company Limited·Phase 1·NCT07408336·18 enrolled

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Recruiting·HHospital Universitario Araba·N/A·NCT07249060·300 enrolled

Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT07283315·12 enrolled

Safety Study of CC312 in Autoimmune Disease Patients

Recruiting·CCytoCares Inc·Phase 1·NCT06888960·18 enrolled

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Recruiting·—·Phase 1·NCT06980597·44 enrolled

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

Recruiting·RRenJi Hospital·Phase 1·NCT06316076·48 enrolled

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Recruiting·SStephan Grupp MD PhD·Phase 2·NCT05029336·20 enrolled

Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases

Recruiting·—·N/A·NCT07121777·18 enrolled

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06941129·12 enrolled

Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)